O&D Biotech

O&D Biotech is a South Korean biopharmaceutical company dedicated to developing innovative treatments for metabolic and age-related diseases by targeting mitochondrial dysfunction. The company's research is centered on small molecule therapeutics that restore cellular energy balance and reduce oxidative stress. Its lead program, OND-101, is a first-in-class mitochondrial function improver currently in Phase 1 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Beyond NASH, O&D Biotech is advancing a pipeline of assets for obesity, type 2 diabetes, and sarcopenia. The company leverages deep expertise in mitochondrial biology to address the underlying pathophysiology of chronic metabolic conditions.